| 1 |
What is the primary function of AI in the medical imaging industry?
|
To improve diagnostic accuracy and patient outcomes |
|
AI in medical imaging is primarily used to assist radiologists by analyzing images quickly and accurately, detecting abnormalities, and helping to diagnose diseases earlier. This enhances the accuracy of diagnoses and leads to better patient care and outcomes. |
Based on machine learning and computer vision principles applied in healthcare. Supported by numerous studies and guidelines from organizations such as the Radiological Society of North America (RSNA) and World Health Organization (WHO). |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 2 |
Which of the following is a key benefit of AI in radiology noted in the article?
|
Acts as a second medical opinion |
|
AI in radiology provides an additional layer of analysis by reviewing medical images alongside radiologists. This “second opinion” helps reduce diagnostic errors, improves confidence in findings, and supports better clinical decisions.
|
Based on principles of computer-aided diagnosis (CAD) and decision support systems in medical imaging. Supported by research from organizations like the Radiological Society of North America (RSNA) and studies in medical informatics. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 3 |
What does AI literacy refer to according to the article?
|
Understanding and knowledge of AI technology |
|
AI literacy refers to the ability to comprehend, critically assess, and effectively use AI technologies. It includes understanding AI concepts, applications, limitations, and ethical considerations, enabling informed decisions and responsible usage. |
Based on digital literacy and technological competency frameworks that emphasize critical thinking and informed use of emerging technologies. Supported by educational guidelines from organizations such as ** UNESCO** and IEEE.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 4 |
Which factor is NOT listed as influencing the acceptability of AI among healthcare professionals?
|
The color of the AI machines |
|
The color of AI machines is irrelevant to healthcare professionals' acceptance of AI. Key factors influencing acceptability include trust, seamless integration with workflows, understanding of the system, and openness to new technology. |
Based on technology acceptance models (TAM) and health informatics research, which identify trust, ease of use, and perceived usefulness as core determinants of technology adoption. Supported by studies in healthcare AI adoption. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 5 |
What role does social influence play in AI acceptability in healthcare according to the article?
|
Affects healthcare professionals’ decisions to use AI |
|
Social influence, such as opinions from colleagues, leaders, and professional communities, significantly affects whether healthcare professionals accept and adopt AI technologies. Peer acceptance and social norms help shape individual decisions. |
Based on Theory of Planned Behavior (TPB) and Technology Acceptance Model (TAM), which highlight social influence as a key factor affecting behavioral intentions and technology adoption. Supported by health informatics research on AI implementation. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 6 |
What is a perceived threat regarding AI usage in healthcare settings?
|
Concerns about replacing healthcare professionals |
|
A common perceived threat of AI in healthcare is the fear that AI might replace human professionals, leading to job insecurity and reduced roles for healthcare workers. This concern can affect the acceptance and implementation of AI technologies. |
Based on technology acceptance models and studies on job displacement fears related to automation and AI in healthcare. Supported by research on human-AI interaction and organizational behavior in medical settings. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 7 |
According to the article, what is essential for increasing AI acceptability among medical professionals?
|
Designing human-centred AI systems |
|
Human-centred AI design focuses on creating AI systems that complement healthcare professionals’ work, are user-friendly, and support decision-making without replacing humans. This approach increases trust, usability, and acceptance among medical staff. |
Based on human-centred design (HCD) principles and technology acceptance models (TAM) that emphasize usability, user involvement, and trust. Supported by research in health informatics and AI ethics from organizations like WHO and IEEE.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 8 |
What does the 'system usage' category of AI acceptability factors include according to the article?
|
Factors like value proposition and integration with workflows |
|
The 'system usage' category refers to practical aspects of AI adoption, including how valuable the AI system is perceived to be (value proposition) and how well it integrates into existing clinical workflows, affecting ease of use and efficiency. |
Based on Technology Acceptance Model (TAM) and Unified Theory of Acceptance and Use of Technology (UTAUT), which emphasize system usefulness and compatibility as key factors influencing technology adoption. Supported by studies in health informatics and AI implementation. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 9 |
How does ethicality impact AI acceptability among healthcare professionals?
|
Affects views on AI based on compatibility with professional values |
|
Ethicality influences how healthcare professionals perceive AI by assessing whether AI systems align with their moral and professional values, such as patient privacy, fairness, and responsibility. This alignment is crucial for acceptance and trust. |
Based on ethical frameworks in technology adoption and professional ethics in healthcare, emphasizing the role of value congruence in technology acceptance. Supported by studies from bioethics and health informatics fields |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 10 |
What methodological approach did the article emphasize for future AI acceptability studies?
|
Considering user experience and system integration deeply |
|
The article highlights the importance of thoroughly examining how users interact with AI systems and how well these systems fit into existing workflows. Understanding user experience and system integration is key to improving AI acceptability among healthcare professionals. |
Based on human-centered design and technology acceptance theories like TAM and UTAUT, which stress the significance of usability and compatibility for successful technology adoption. Supported by research in health informatics and AI implementation studies. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 11 |
What is the primary objective of using human embryonic stem cells in treating Parkinson’s disease?
|
To replace lost dopamine neurons. |
|
Parkinson’s disease involves the loss of dopamine-producing neurons in the brain. Human embryonic stem cells can differentiate into these specific neurons, potentially restoring dopamine levels and improving motor function in patients. |
Based on stem cell therapy and regenerative medicine principles, where stem cells replace damaged or lost cells. Supported by studies in neuroscience and clinical trials focused on Parkinson’s disease treatment.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 12 |
Which animal was used to test the STEM-PD product for safety and efficacy?
|
Monkeys |
|
Non-human primates like monkeys are often used in preclinical studies for neurological diseases because their brain structure and function are closer to humans compared to rodents. Testing the STEM-PD product in monkeys helps better predict safety and efficacy before human trials. |
Based on principles of translational research and preclinical testing that prioritize animal models with physiological similarities to humans. Supported by neuroscience and pharmacology research protocols.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 13 |
What was the duration of the preclinical safety study in rats mentioned in the article?
|
6 months |
|
Preclinical safety studies often span several months to observe any potential toxic effects over time. The article mentions a 6-month duration for the rat study to adequately assess the safety of the treatment before progressing to human trials. |
Based on standard toxicology testing protocols and regulatory guidelines for preclinical studies, which require sufficient timeframes to detect delayed or cumulative adverse effects. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 14 |
What is the name of the clinical trial phase mentioned for STEM-PD?
|
Phase I/IIa |
|
The clinical trial for STEM-PD is described as a combined Phase I/IIa study, which typically focuses on evaluating safety (Phase I) and early signs of efficacy (Phase IIa) in a small group of participants. |
Based on standard clinical trial phases where Phase I assesses safety and dosage, and Phase IIa explores preliminary efficacy and side effects. This combined approach is common in early-stage trials for novel therapies. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 15 |
How is the STEM-PD product manufactured?
|
Under GMP-compliant conditions |
|
The STEM-PD product is manufactured following Good Manufacturing Practice (GMP) standards to ensure quality, safety, and consistency. GMP compliance is essential for producing clinical-grade materials for human use and meeting regulatory requirements |
Based on regulatory standards in pharmaceutical and cell therapy manufacturing which mandate GMP compliance to ensure products are safe and effective. Supported by guidelines from agencies like the FDA and EMA.
|
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 16 |
According to the article, what confirmed the safety of the STEM-PD product in rats?
|
There were no adverse effects or tumor formation. |
|
The safety of the STEM-PD product in rats was confirmed by the absence of harmful side effects, including no tumor development or other adverse reactions, indicating that the treatment is safe for further testing. |
Based on standard toxicology and safety assessment protocols in preclinical studies, where the lack of adverse events is critical for advancing to clinical trials. Supported by regulatory guidelines for cell therapy safety. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 17 |
What key finding was noted in the efficacy study of STEM-PD in rats?
|
Transplanted cells reversed motor deficits in rats. |
|
The efficacy study showed that stem cells transplanted into rats were able to improve motor function, indicating successful differentiation into dopamine neurons and functional integration to counter Parkinson’s disease symptoms. |
Based on principles of cell replacement therapy and functional recovery in neurodegenerative disease models, where improvement in motor skills indicates therapeutic benefit. Supported by preclinical neuroscience research. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 18 |
What specific markers were used to assess the purity of the STEM-PD batch?
|
GIRK2 and ALDH1A1 |
|
GIRK2 and ALDH1A1 are specific markers used to identify and confirm the purity of dopamine neuron precursors derived from stem cells. These markers indicate successful differentiation toward the desired cell type relevant for Parkinson’s therapy. |
Based on stem cell biology and neurodevelopmental markers, where GIRK2 and ALDH1A1 are recognized markers of midbrain dopaminergic neurons. Supported by research in regenerative medicine and Parkinson’s disease cell therapy. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 19 |
What role do growth factors like FGF8b and SHH play in the manufacturing process of STEM-PD?
|
They are used in cell patterning for specific neural fates. |
|
Growth factors like FGF8b (Fibroblast Growth Factor 8b) and SHH (Sonic Hedgehog) are critical signaling molecules used during stem cell differentiation to guide cells toward becoming specific types of neurons, such as midbrain dopaminergic neurons, essential for Parkinson’s disease therapy |
Based on developmental biology and stem cell differentiation principles where morphogens like FGF8 and SHH regulate neural patterning and fate specification. Supported by neuroscience and regenerative medicine studies. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|
| 20 |
What was a key outcome measured in the preclinical trials for efficacy in rats?
|
Recovery of motor function |
|
In preclinical trials for Parkinson’s disease, the primary efficacy outcome is often the improvement or recovery of motor function, as motor deficits are a hallmark symptom. Successful stem cell therapy should restore movement abilities. |
Based on Parkinson’s disease pathology and functional recovery models in neuroscience research, where motor function is a key clinical endpoint. Supported by preclinical and translational studies. |
7 |
-.50
-.25
+.25
เต็ม
0
-35%
+30%
+35%
|